Gain Therapeutics, Inc. (GANX)
Gain Therapeutics develops small molecule drugs for neurological and rare genetic diseases, based in Bethesda, Maryland. It last closed at $1.18 on Nov 17, up 25.51% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From GANX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on GANX in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $1.18.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 31 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| Aug 12 | BTIG | Reiterated | Buy | $5 |
| Jul 1 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| Jun 30 | BTIG | Maintained | Buy | $5 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 53% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the Pivot at $1.15, and the nearest resistance the swing high (Nov 4) at $1.20.
| RSI (14) | 48.26 | Middle of its range | Neutral |
| MACD | -0.11 | Above its signal line | Bullish |
| Stochastic | 32.9 | Middle of its range | Neutral |
| ADX (14) | 33.5 | Trending up | |
| Williams %R | -33.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 19.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +2.6% | Change over 10 sessions | Bullish |
| ATR (14) | $0.12 | Typical daily range, 10.6% of price |
| RSI (14) | 37.09 | Weak, oversold below 30 | Neutral |
| MACD | -0.22 | Below its signal line | Bearish |
| Stochastic | 11.0 | Near the bottom of its range | Oversold |
| ADX (14) | 14.2 | No clear trend | |
| Williams %R | -80.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -120.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −32.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.27 | Typical daily range, 23.1% of price |
What happened before
See how GANX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GANX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in GANX in the last 90 days.
GANX Institutional Ownership
Full report →- ●19 buying vs 21 selling
- ▼Held by funds -1.8 pts
- ●Funds holding +0
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 50 | 50 | 0.0% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 19.0% | 20.7% | −1.8 pts |
| New / increased | 9 / 10 | 12 / 15 | −29.6% |
| Reduced / sold out | 11 / 10 | 9 / 4 | +61.5% |
| Put/call ratio | 0.00 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GANX is in one of them and how their past GANX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GANX in an article yet. Here's the latest on the wider market.
About Gain Therapeutics
Gain Therapeutics is a biotechnology company in Bethesda, Maryland, that develops small molecule drugs for diseases caused by misfolded proteins. Its lead candidate, GT-02287, is being tested for Parkinson's disease. The company is also working on treatments for lysosomal storage disorders, metabolic disorders and oncology. It uses its Magellan computational platform to find sites on disease-linked proteins where drugs can bind and to design molecules that fit those sites.
- Headquarters
- Bethesda, MD

